What We Can Learn From Bill Ackman Walking Away From Valeant Pharmaceuticals Intl Inc.

Investors can learn a lot from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
The Motley Fool

Recently, it was announced that hedge fund manager Bill Ackman sold his firm’s entire stake in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). By selling his final position, he has done what many investors hate to do: he locked in losses.

Almost every investor has at least one position in their portfolio that is held at a loss. When an investor enters a position and sees the investment decline in value by say 20%, it is important to understand what needs to happen for the investor to be able to recoup their original investment. Using very simple math, an investment of $100 which declines by 20% to $80 needs to return to $100 for the investor to be even.

Assuming we hit the reset button here, a new investor may purchase the shares at $80 and get a $20 return divided by the initial outlay of $80, which translates to a return of 25%, not 20%!

For investors holding positions that are slightly at a loss, the amount a stock must come back to make up the loss is nothing more than a rounding error. Once it gets beyond 20-25%, however, the numbers are a little more serious.

With a loss of 10% as an example, the return must be 10/90 = 11.1%, meaning a difference of 1.1% — a very minor number.

Valeant shares have declined close to 90% since Ackman made the initial investment, translating to a return of (90/10) = 900% for his firm to get back to even. Although we’ve seen the hedge fund manager do fantastic things in the past, any investor hoping for a return of 900% is dreaming.

The amount of interest expenses as a percentage of revenue is simply too high for this company to survive over the long term, translating to a desperate need to either drastically increase revenue or repay debt.

As it is difficult to increase revenues, the second option is to pay off debt. Debt is close to $30 billion, and that can only mean selling assets or doing a secondary share issue. The challenge with this possibility is that Valeant has $30 billion in debt but a market capitalization of only approximately $5 billion. If the float were to double, the debt would only be reduced by approximately 16.5% or so.

And it seems the company is in for the fight of a lifetime after losing one of the heavyweight members of the board of directors.

Although the company has many excellent products to offer consumers, the reality is, the debt burden is simply too much to carry at this point. Bankruptcy may take months from here, but it’s inevitable — the fat lady will sing!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Goldsman has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A plant grows from coins.
Dividend Stocks

Dividend Stocks: What’s Better? Growth or Consistency?

Are you trying to invest in dividend stocks? What’s better, growth or consistency? Here’s my take.

Read more »

Stocks for Beginners

After Hitting 52-Week Highs, TIH Stock Is Down: Here’s What Happened

TIH (TSX:TIH) stock has seen a huge rally in 2023, but dropped earlier in April as an analyst weighed in…

Read more »

stock market
Investing

2 Top TSX Bargain Stocks That Could Be Ready for a Bull Run

These 2 TSX stocks are already rallying on recent results that have been stronger than expected.

Read more »

Cogs turning against each other
Dividend Stocks

How to Build a Bulletproof Monthly Passive Income Portfolio With Just $5,000

Looking for solid stocks for a bulletproof income portfolio? Consider adding these two REITs.

Read more »

Gold bullion on a chart
Energy Stocks

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

Torex Gold Resources (TSX:TXG) stock and one undervalued TSX energy stock could rise as identified scenarios play out.

Read more »

clock time
Dividend Stocks

Is Now the Right Time to Buy goeasy Stock? Here’s My Take

Shares of goeasy stock (TSX:GSY) slumped last year on a federal announcement, but that has all changed since then.

Read more »

Illustration of bull and bear
Investing

The Bulls Are Coming: 2 of the Best Growth Stocks to Buy Now to Get Ahead

Alimentation Couche-Tard (TSX:ATD) and MTY Food Group (TSX:MTY) stocks look way too cheap to ignore at these levels.

Read more »

Bank sign on traditional europe building facade
Stocks for Beginners

1 Magnificent TSX Dividend Stock Down 22% to Buy and Hold Forever

This dividend stock may be down 22% from all-time highs, but is up 17% in the last year alone. And…

Read more »